| Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine J Sadoff, M Le Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... New England Journal of Medicine 384 (19), 1824-1835, 2021 | 1227 | 2021 |
| Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial I Leroux-Roels, A Borkowski, T Vanwolleghem, M Dramé, F Clement, ... The Lancet 370 (9587), 580-589, 2007 | 561 | 2007 |
| Respiratory syncytial virus prefusion F protein vaccine in older adults A Papi, MG Ison, JM Langley, DG Lee, I Leroux-Roels, F Martinon-Torres, ... New England Journal of Medicine 388 (7), 595-608, 2023 | 303 | 2023 |
| Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial JJ De Waele, S Carrette, M Carlier, V Stove, J Boelens, G Claeys, ... Intensive care medicine 40, 380-387, 2014 | 214 | 2014 |
| Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine … I Leroux-Roels, S Forgus, F De Boever, F Clement, MA Demoitié, ... Vaccine 31 (17), 2196-2206, 2013 | 179 | 2013 |
| A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults I Leroux-Roels, G Leroux-Roels, F Clement, P Vandepapelière, ... The Journal of infectious diseases 206 (8), 1280-1290, 2012 | 170 | 2012 |
| Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine I Leroux-Roels, R Bernhard, P Gerard, M Drame, E Hanon, ... PloS one 3 (2), e1665, 2008 | 169 | 2008 |
| H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses P Moris, R van der Most, I Leroux-Roels, F Clement, M Dramé, E Hanon, ... Journal of clinical immunology 31, 443-454, 2011 | 159 | 2011 |
| Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults I Leroux-Roels, E Vets, R Freese, M Seiberling, F Weber, C Salamand, ... Vaccine 26 (51), 6614-6619, 2008 | 156 | 2008 |
| Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial C Aldrich, I Leroux–Roels, KB Huang, MA Bica, E Loeliger, ... Vaccine 39 (8), 1310-1318, 2021 | 146 | 2021 |
| Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open … I Leroux-Roels, F Roman, S Forgus, C Maes, F De Boever, M Dramé, ... Vaccine 28 (3), 849-857, 2010 | 146 | 2010 |
| An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults K Levie, I Leroux-Roels, K Hoppenbrouwers, AD Kervyn, ... The Journal of infectious diseases 198 (5), 642-649, 2008 | 137 | 2008 |
| Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled … PG Kremsner, RAA Guerrero, E Arana-Arri, GJA Martinez, M Bonten, ... The Lancet Infectious Diseases 22 (3), 329-340, 2022 | 125 | 2022 |
| Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial J Sadoff, ML Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... MedRxiv, 2020.09. 23.20199604, 2020 | 112 | 2020 |
| Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers P Kremsner, P Mann, J Bosch, R Fendel, JJ Gabor, A Kreidenweiss, ... MedRxiv, 2020.11. 09.20228551, 2020 | 94 | 2020 |
| Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems I Leroux-Roels, M Koutsoukos, F Clement, S Steyaert, M Janssens, ... Vaccine 28 (43), 7016-7024, 2010 | 94 | 2010 |
| Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial PG Kremsner, P Mann, A Kroidl, I Leroux-Roels, C Schindler, JJ Gabor, ... Wiener Klinische Wochenschrift 133 (17-18), 931-941, 2021 | 93 | 2021 |
| Current status and progress of prepandemic and pandemic influenza vaccine development I Leroux-Roels, G Leroux-Roels Expert review of vaccines 8 (4), 401-423, 2009 | 81 | 2009 |
| Safety and Immunogenicity of the Ad26 J Sadoff, M Le Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... COV2. S COVID-19 Vaccine Candidate: Interim Results of a Phase 1/2a, Double …, 2020 | 77 | 2020 |
| Evaluation of the immune response to RTS, S/AS01 and RTS, S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive adults G Leroux-Roels, I Leroux-Roels, F Clement, O Ofori-Anyinam, M Lievens, ... Human vaccines & immunotherapeutics 10 (8), 2211-2219, 2014 | 67 | 2014 |
